For more information about these heart research studies, call 320-251-2700, ext. 57584 or e-mail Heart Research.
CentraCare Heart & Vascular Center takes an active role in heart research. Our goal is to find better ways to prevent, diagnose and treat heart disease so you can live better and longer.
Why participate in heart research?
- Early access to new drugs and treatments
- Help others who have heart problems, both today and in the future
- Play a role in the discovery of new drugs, treatments and cures
As one of Minnesota's largest heart hospitals, we are one of the few sites in the state with a department dedicated to heart research.
Current research studies
Accelerate: This study looks at the safety of an investigational drug (Evacetrapib) and how well it works on people diagnosed with “high risk vascular disease.”
AMG-145 20110118 FOURIER: This study looks at an investigational product called AMG 145. It sees whether treatment of dyslipidemia (abnormal amounts of lipids in the blood) with AMG 145 reduces the risk of recurring or additional cardiovascular events in people who have experienced a prior heart attack or stroke and who are taking a highly effective dose of a statin.
EUCLID: Patients with peripheral arterial disease (PAD) are at a significant risk to have heart problems and stroke. This study looks to see if a new medication called ticagrelor, given twice daily, is effective in preventing the occurrence of heart attack, stroke and/or death due to heart problems in patients who have PAD and if so, how it compares with clopidogrel (Plavix), given once daily.
GLORIA-AF: This is a registry study for patients recently diagnosed with atrial fibrillation.
Odyssey: The purpose of this study is to determine whether a study drug (SAR236553) might prevent future cardiovascular events (such as, heart attacks or strokes) in patients who recently experienced a coronary event.
REDUCE-IT: AMR101 has been investigated as a therapy to lower triglyceride levels. It is thought that AMR101, in combination with a statin drug (such as Lipitor®), will have a greater effect in preventing a cardiovascular event (like a heart attack or stroke) than if you were taking a statin drug alone.
TAK-875_306: This study is for patients with type 2 diabetes who also have cardiovascular disease (heart attack, stroke, peripheral vascular disease, etc.) or are considered to have multiple risk factors for cardiovascular events (for example, you have had type 2 diabetes for more than 10 years, you smoke, have high blood pressure, etc.). The study aims to learn about the cardiovascular safety of TAK-875 (the investigational drug) when given with standard medications for type 2 diabetes in people at risk for cardiovascular disease (CVD).
Cantos: The study looks to see if the study drug canakinumab, which reduces inflammation, is both safe and beneficial in reducing future cardiovascular events (such as heart attacks and strokes) in patients who have had a heart attack and ongoing increased inflammation. This study also will test whether or not canakinumab reduces the development of type 2 diabetes if you had abnormal blood sugar levels after your heart attack.
PROMISE: The study compares different, routinely-performed heart tests, such as exercise electrocardiogram (ECG), stress echocardiogram (echo), stress nuclear test and coronary computed tomography.
AMG-145 20120153 GLAGOV: This study looks at the changes in the fatty deposits in the walls of the blood vessels of your heart and blood levels of your “good” and “bad” cholesterol when AMG 145 is taken along with your present medical therapy as directed by your doctor, including a medication for the treatment of abnormal cholesterol blood levels called “statins.” AMG 145 and placebo are given by subcutaneous injection. A subcutaneous injection is an injection given into the tissue just below the skin. In this study, the effects of AMG 145 will be determined by an intravascular ultrasound (IVUS) procedure that measures the amount of fatty deposits in the arteries of your heart.
Amplatzer Cardiac Plug (ACP): The study evaluates the safety and effectiveness of the AMPLATZER Cardiac Plug. It will compare the results of this device to standard therapy with the medicines warfarin or dabigatran. The AMPLATZER Cardiac Plug is a self-expanding device made from a nitinol (nickel-titanium alloy) mesh. It has a lobe and a disc connected by a central waist. The device is designed to prevent blood clots from moving out of the left atrial appendage (LAA).
Other Heart Procedure Studies
This is a registry for patients who received a procedure called carotid stent supported angioplasty. More information
Medtronic Attain Performa: Patients who receive a Resynchronization Therapy (CRT) device may be eligible for this study. The study evaluates the safety and efficacy of Medtronic Attain Performa Quadripolar Leads during and post the implant procedure. This study also will assess the interactions of the Attain Performa leads with the entire Medtronic CRT-D system.
The CentraCare Heart & Vascular Center Research Department undergoes rigorous review from the St. Cloud Hospital Institutional Review Board (IRB). The purpose of the IRB is to protect the rights and safety of people who volunteer to take part in research studies. To contact the IRB, call 320-255-5785.